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Abstract 
Chemotherapy-induced neuropathic pain is a debilitating and common side effect of cancer 
treatment. Mitochondrial dysfunction associated with oxidative stress in peripheral nerves 
has been implicated in the underlying mechanism. We investigated the potential of 
melatonin, a potent antioxidant that preferentially acts within mitochondria, to reduce 
mitochondrial damage and neuropathic pain resulting from the chemotherapeutic drug 
paclitaxel. In vitro, paclitaxel caused a 50% reduction of mitochondrial membrane potential 
and metabolic rate, independent of concentration (20-100µM). Mitochondrial volume was 
increased dose-dependently by paclitaxel (200% increase at 100µM). These effects were 
prevented by co-treatment with 1µM melatonin. Paclitaxel cytotoxicity against cancer cells 
was not affected by co-exposure to 1µM melatonin of either the breast cancer cell line MCF-
7, or the ovarian carcinoma cell line A2780. In a rat model of paclitaxel-induced painful 
peripheral neuropathy, pre-treatment with oral melatonin (5/10/50mg/kg), given as a daily 
bolus dose, was protective, dose-dependently limiting development of mechanical 
hypersensitivity (19/43/47% difference from paclitaxel control, respectively). Melatonin 
(10mg/kg/day) was similarly effective when administered continuously in drinking water (39% 
difference). Melatonin also reduced paclitaxel-induced elevated 8-isoprostane F2 levels in 
peripheral nerves (by 22% in sciatic; 41% in saphenous) and limited paclitaxel-induced 
reduction of C fibre activity-dependent slowing (by 64%). Notably melatonin limited the 
development of mechanical hypersensitivity in both male and female animals (by 50/41%, 
respectively) and an additive effect was found when melatonin was given with the current 
treatment, duloxetine (75/62% difference, respectively). Melatonin is therefore a potential 
treatment to limit the development of painful neuropathy resulting from chemotherapy 
treatment.  
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1. Introduction 
 
A common side effect of cancer treatment is chemotherapy-induced neuropathic pain (CINP) 
which can be severe enough to require dose reduction or treatment cessation, with consequent 
effects on survival and the quality of life of patients with cancer.1,2 This predominantly sensory 
neuropathy  affects up to 68% of patients in the first month after finishing chemotherapy, with 
around 30% of patients  still being symptomatic more than 6 months later1. CINP may not 
resolve, and in some cases can worsen with time.  Current treatment options are based mainly 
on evidence from other types of neuropathic pain,3 Duloxetine, a serotonin-norepinephrine re-
uptake inhibitor, is one of the few agents with direct evidence of efficacy for CINP.4 All of the 
currently used agents have significant limitations both in terms of efficacy and side effects. 
There is an urgent need for a treatment which addresses the neuropathic mechanisms, and 
can prevent or alleviate CINP. 
 
Paclitaxel is a commonly used chemotherapeutic with a high incidence of CINP.1 It has been 
shown to cause mitochondrial dysfunction in vitro5 and in peripheral nerves and dorsal root 
ganglia in vivo,6,7 associated with oxidative stress. Administration of mitochondrial poisons in 
animals exacerbated paclitaxel-induced neuropathic pain,8 whilst global radical scavengers 
(spin traps)9, mitochondrial electron transport chain modulators10 and reduction of 
mitochondrial damage with a small molecule P53 inhibitor11 or acetyl carnitine12 was 
associated with decreases in neuropathic pain behaviours. These studies support the notion 
that CINP induced by paclitaxel is mediated by oxidative damage to mitochondria, and 
suggests that targeting treatments specifically at mitochondria may be beneficial. Our previous 
work showed that the mitochondria targeted antioxidant MitoVitE was able to reduce 
mechanical hypersensitivity in rats treated with paclitaxel.13 However MitoVitE has not been 
through Phase I studies and its use cannot be rapidly translated into the clinical arena.  
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We have previously reported that MitoVitE and melatonin are equally effective at reducing 
mitochondrial dysfunction and markers of inflammation in other disease models both in vitro 
and in animals.14 Melatonin, like MitoVitE, is able to accumulate inside mitochondria and is a 
potent antioxidant; its metabolites and reaction products are also effective.15,16 Melatonin has 
been given safely to humans with no evidence of toxicity even at very high doses.17 We 
therefore hypothesised that melatonin would reduce mitochondrial damage induced by 
paclitaxel in neuronal cells in vitro and would alleviate, and/or limit the development of, 
mechanical hypersensitivity and altered peripheral nerve function in a pre-clinical rat model of 
paclitaxel-induced painful neuropathy.  
 
2. Materials and methods 
2.1 In vitro studies 
The 50B11 immortalized dorsal root ganglion (DRG) neuronal stem cell line was kindly 
donated by Professor Ahmet Hoke, from Johns Hopkins School of Medicine, Baltimore, MA, 
USA. These cells have nociceptive properties: after differentiation they extend neurites and 
generate action potentials when depolarized, express key nociceptive markers and respond 
to capsaicin.18 Culture and maintenance of these cells is described in our previous study.13 
They were differentiated into DRGs by exposure to 75µM forskolin for 24 hours, with outgrowth 
of neurites starting after about 10 hours. After differentiation, a range of concentrations of 
paclitaxel was added with and without 1µM melatonin or relevant solvent control for 24 hours.  
 
2.1.1 Mitochondrial function  
Mitochondrial function was determined in intact cells after 24 hours treatment, by 
measurement of the mitochondrial membrane potential using the fluorescent probe JC-1 
(5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide, Invitrogen, Paisley, 
UK), and by measurement of metabolic activity using the rate of reduction of AlamarBlue™ 
(Invitrogen).13,15  Mitotracker Green FM™(Invitrogen) was used to determine mitochondrial 
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volume.19-21 Cell viability after treatments was measured as acid phosphatase activity as we 
have described previously and measures of mitochondrial function were corrected for viable 
cell number.22 
 
2.1.2 Cancer cell cytotoxicity 
As melatonin might affect the cytotoxic capacity of paclitaxel against cancer cells, we 
measured paclitaxel-induced killing of the breast adenocarcinoma-like oestrogen-sensitive cell 
line, MCF-7, and the ovarian carcinoma cell line, A2780, in the presence of melatonin. Cancer 
cells were cultured for 24 hours with 0-100 µM paclitaxel with and without 1µM melatonin or 
solvent control as we have described for MitoVitE previously.13 Acid phosphatase activity was 
used to assess cell viability as for DRG cells. 
 
2.2 Animal model 
The animal work was approved by the UK Home Office and carried out in accordance with 
Animals (Scientific Procedures) Act 1986, following applicable aspects of the ARRIVE 
Guidelines.23 Animal health and welfare was paramount throughout all studies and animals 
were checked daily for any signs of distress. Weight gain and cage behaviour were continually 
recorded. All animals were handled as gently as possible, and cage bedding was ample, to 
provide a soft environment.  
Male and female Sprague Dawley rats weighing approximately 300g were housed with a 
maximum of 6 (single sex) per cage in standard conditions, at 19-22°C, on a 12-hour light/dark 
cycle from 7am to 7pm. Food and drinking water were provided ad libitum. The rats were kept 
in the experimental area for a minimum of three days before baseline testing was started. 
Details of the model have been published previously13,24 and are described only briefly here. 
As rats were group housed treatment group allocation was undertaken by cage rather than 
individual animal to avoid contamination by coprophagia. Rats received either 4 x doses of 
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2mg/kg paclitaxel or Cremophor/EL (polyethoxylated castor oil, the vehicle control for 
paclitaxel) diluted in saline, by intraperitoneal (i.p.) injection every second day.  
 
2.2.1 Behavioural assessment of mechanical sensitivity  
Pseudo-blinding of treatment allocation was achieved by mixing animals from all treatment 
groups immediately before testing; group allocation was only confirmed by tail number when 
testing was complete. Prior to mechanical sensitivity testing, animals were acclimatised in two 
x 20 minute sessions on separate days, and further habituated for 20 minutes immediately 
before testing on any given day. Hind paw plantar withdrawal thresholds to von Frey filaments 
were determined every 2-6 days throughout the model, using the up-down method,25 as we 
have described previously.13  
 
2.2.2 Effect of bolus doses of melatonin  
To assess the effect of pre-treatment with bolus doses of melatonin, male rats (n=5-6 per 
group) were given one of three bolus doses of melatonin (5, 10 or 50mg/kg, 2µl/g body weight) 
or 10% ethanol vehicle control by daily oral gavage (between 10:00 and 11:00hrs) starting 3 
days prior to paclitaxel or control treatment. Mechanical sensitivity was measured 1, 6, and 24 
hours after gavage every second or third day. In a separate study male rats were given a bolus 
dose of 10 mg/kg melatonin by oral gavage, then blood samples were obtained by cardiac 
puncture from groups of rats (n=3 per group) at 1, 2, 6, 12, 24 and 48 hours after dosing, or 
untreated controls, to determine the pharmacokinetics of melatonin.  
 
 
2.2.3 Effect of melatonin given in drinking water  
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We also administered melatonin (10mg/kg/day) or vehicle control (0.1% v/v ethanol) in 
drinking water starting 3 days before paclitaxel treatment, to groups of male rats (n=5-6 per 
group). A control group received saline (i.p.) plus melatonin in drinking water to determine 
whether melatonin impacted upon baseline mechanical sensitivity. To maintain 10mg/kg/day 
melatonin dose, the concentration of melatonin was adjusted to account for mean water 
consumption over the previous two days, and average current weight of rats in a given cage.  
Opaque bottles were used and changed every 2 days. Levels of melatonin in drinking water 
were measured as described for serum below to confirm that melatonin levels were stable for 
at least 48 hours under these conditions. The actual levels of water consumption were 
consistently similar to that of water with vehicle control. After experimentation, blood was 
collected by cardiac puncture and serum melatonin levels were determined. 
The effect of discontinuing or starting melatonin treatment after mechanical hypersensitivity 
had developed was also assessed. Groups of rats (n=6) received either melatonin or vehicle 
control in drinking water continuously starting 3 days before paclitaxel as above; melatonin 
starting 3 days before paclitaxel then stopping (reverting to vehicle control) at day 18 once the 
hypersensitivity was apparent; or vehicle starting 3 days before paclitaxel then commencing 
melatonin treatment at day 20 once the hypersensitivity was fully established.  
The combination of melatonin with the current CINP treatment, duloxetine, was also assessed. 
By targeting multiple mechanisms,26 we hypothesised an additive effect on paclitaxel-induced 
mechanical hypersensitivity. Given increasing awareness of sex differences in pain and 
analgesic sensitivity,27,28 this was investigated in both sexes. Male and female rats (n=6 per 
group) were given melatonin or vehicle control in drinking water starting 3 days before 
paclitaxel as above, plus daily i.p. injections of duloxetine (10mg/kg/day; 1µl/g body weight) or 
vehicle control (20% ethanol in saline), starting when the mechanical hypersensitivity had 
established.  
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2.2.4 Sedation testing 
Prior to behavioural testing, rats were assessed on a five-point scale for righting reflexes: 0 
the rat struggles when placed on its side, followed by rapid forceful righting; 1 moderate 
resistance when the rat is placed on its side, with rapid but not forceful righting; 2 no resistance 
to the rat being placed on its side, with effortful but ultimately successful righting; 3 
unsuccessful righting; 4 no movements.29 
 
2.2.5 Serum melatonin levels 
Rats were anesthetized by brief inhalation of isoflurane followed by overdose of 20% w/v 
pentobarbitone (~1g/kg) given by i.p. injection. The chest cavity was rapidly opened and the 
right atrium was punctured to collect blood for serum samples. Melatonin levels were 
determined in serum and drinking water using a Thermo Surveyor-TSQ Quantum liquid 
chromatography tandem mass spectrometry (LC-MS/MS) system (Thermo Scientific, Hemel 
Hempstead, UK). This assay has a lower limit of quantitation of 0.5 ng/mL and high inter- and 
intra-assay precision, as we have previously described in detail.17  
 
2.2.6 8-isoprostane F2 levels  
F2-isoprostanes, which are one of the most reliable measures of oxidative stress status in 
vivo,30 were measured ex vivo in peripheral nerve tissue 19 days after paclitaxel/cremophor 
treatment and included experimental animals from the bolus dosing experiments receiving 
melatonin at 10 mg/kg or vehicle treatment. Rats were decapitated under isoflurane 
anaesthesia and sciatic and saphenous nerve tissue were removed, placed in ice cold 0.1M 
phosphate buffer and homogenised, then centrifuged and frozen at -80°C. Tissue was 
collected throughout the day with animals from different treatment groups interleaved to 
ensure all treatment groups were collected over comparable time windows. F2 levels were 
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assessed using a commercially available 8-isoprostane F2 elisa kit (Enzo Lifesciences, 
Exeter, UK).  The lower limit of detection is 40mg/ml with median intra- and inter-assay 
coefficients of variation of 5.7 and 5.8% respectively. 
 
2.2.7 C fibre activity-dependent slowing 
C fibre function was assayed by quantifying C fibre activity-dependent slowing (ADS) in 
peripheral nerve tissue from male rats receiving cremophor or paclitaxel with and without 
10mg/kg melatonin in drinking water 14-18 days following the start of paclitaxel or vehicle 
treatment. Rats were decapitated under isoflurane anaesthesia, at the same time in the 
morning, and lumbar (L4/5) dorsal roots, minus dorsal root ganglia, were isolated and 
incubated at 36°-37°C in oxygenated recovery solution for 1 hour. Following incubation, tissue 
was transferred to the recording bath of an upright (Zeiss) microscope, and continuously 
perfused with oxygenated Krebs’ solution (1-2ml/min) at room temperature. The 95% O2/5% 
CO2 saturated Krebs’ solution contained (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 
NaHCO3 25 Glucose, 1 MgCl2, 2 CaCl2 pH7.4. Recovery solution was identical to Krebs’ 
solution apart from 6mM MgCl2, 1.5mM CaCl2.  
Compound action potential recordings were carried out using two glass suction electrodes, 
one for electrical stimulation and the second for field potential recording, as we have described 
previously.31,32 Dorsal roots were stimulated with an Iso-flex stimulus isolator (A.M.P.I. 
Jerusalem, Israel) and data were acquired and recorded using a Cygnus ER-1 differential 
amplifier (Cygnus Technologies Inc. Pennsylvania, US) and pClamp 10 software (Molecular 
Devices California, US). Data were filtered at 10kHz and sampled at 50kHz. 
The characteristic triphasic (positive-negative-positive) C fibre component of the compound 
action potential was identified, based on activation threshold and conduction velocity, which 
were not altered by treatment (Table 1).  
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To assess the frequency dependent phenomenon of C fibre ADS,33,34 dorsal roots were 
stimulated x40 (500μA intensity, 0.1ms duration) at frequencies of 1Hz and 2Hz. For each 
stimulus, the response width (first to last positive peak), indicative of the range of conduction 
velocities within the C fibre population, was measured and the change in width from stimulus 
1 calculated. Width change was normalised to the length of root stimulated, measured as the 
distance between the recording and stimulating electrodes.  
 
2.2.8 Statistical analysis 
For in vitro studies, 6 separate experiments with 4 technical replicates were undertaken (n=6). 
Data are presented as median, interquartile and full range and statistical analysis was 
undertaken using Analyse-it Add-in for Microsoft Excel (Analyse-it Software Ltd., Leeds, UK). 
Kruskal Wallis analysis of variance was used for each in vitro treatment, with Mann Whitney 
post hoc testing and correction for multiple comparisons as appropriate.  
 
For in vivo studies, area under the curve (AUC) of mechanical thresholds or C fibre ADS were 
first calculated, then all data were analysed by one-way or two-way ANOVA with appropriate 
post-hoc testing as detailed (GraphPad Prism 7 Software Inc., California, US). Behavioural 
and C fibre ADS data are shown as mean and SD; 8-isoprostane F2  data are presented as 
median, interquartile and full range.  
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3. Results 
3.1 In vitro studies 
3.1.1 Cancer cell cytotoxicity 
Paclitaxel caused loss of DRG cell viability of cancer cells such that median [range] viability in 
A2780 cells was 60.0 [52.1-68.6]% in the presence of 100µM paclitaxel without melatonin and 
56.6 [48.0-64.3]% with 100µM paclitaxel plus 1µM melatonin. Viability of MCF7 cells was 39.2 
[15.8-41.3]% with paclitaxel without melatonin and 36.3 [18.9-55.4]% with melatonin, 
indicating that cell killing by paclitaxel was not reduced by co-exposure of cells to melatonin 
in either of the cancer cell lines. 
 
3.1.2 Mitochondrial function  
Treatment of DRG cells with paclitaxel without melatonin resulted in significantly reduced 
mitochondrial membrane potential as shown by a ~50% reduction in JC-1 red/green 
fluorescence ratio, regardless of dose (p<0.0001, Fig 1A). When cells were co-exposed to 
paclitaxel plus melatonin, membrane potential actually increased except at the highest 
concentration of paclitaxel (Fig 1A). Mitochondrial metabolic activity was also significantly 
reduced when DRG cells were treated with paclitaxel, independently of dose (p<0.0001, Fig 
1B); no such reduction was seen when cells were co-treated with melatonin (Fig 1B). 
Paclitaxel exposure of DRG cells caused a marked dose dependent increase in mitochondrial 
volume (Fig 1C, P<0.0001) and in cells co-treated with melatonin, this effect was not seen (Fig 
1C). 
 
3.2 In vivo studies 
Melatonin administration did not produce sedative effects; all rats, irrespective of treatment, 
scored zero on the five-point scale for righting reflexes (data not shown). Melatonin also did 
not impact upon weight gain in any experimental group tested (supplemental Fig 1). 
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3.2.1 Bolus dosing with melatonin 
Paclitaxel administration caused a reduction in mechanical withdrawal threshold values that 
developed progressively over 2 weeks, as we have shown previously13 (Fig 2A). Rats 
receiving paclitaxel plus melatonin by oral gavage had less mechanical hypersensitivity 
compared with rats given paclitaxel plus vehicle (Fig 2A and B, p<0.0001). AUC analysis of 
mechanical withdrawal thresholds revealed that melatonin limited mechanical hypersensitivity 
at all three doses given. However there was no additional effect of 50mg/kg melatonin 
compared to 10mg/kg. Notably the reduction in hypersensitivity was independent of when 
sensitivity testing was performed in relation to dosing, since similar effects were observed 
when testing was performed at 1, 6 or 24 hours after the bolus dose was given (Fig 2B). In 
contrast, there was a marked increase (~400-fold) in serum melatonin levels at 1h after dosing, 
which had returned to baseline values by 24 hours (Fig 2C). Six rats were allocated to each 
treatment group at the start of the study, however, data from 3 rats (x1 vehicle, x1 5mg/kg 
melatonin, x1 50 mg/kg melatonin treated) was excluded as they were euthanized before the 
end of the study due to complications with repeated oral gavage.  
 
3.2.2 Melatonin in drinking water 
Administration of melatonin in drinking water facilitated longer term monitoring of the effect of 
melatonin upon paclitaxel-induced mechanical hypersensitivity that progressively develops 
over 2 weeks before then plateauing at peak hypersensitivity for around 2 weeks (Fig 3A). 
Melatonin alone did not affect mechanical sensitivity in naïve subjects as assessed using AUC 
analysis of mechanical withdrawal thresholds (Fig. 3A and B). Melatonin, therefore does not 
appear to produce sedative effects that would confound assessment of its effect upon 
mechanical hypersensitivity in neuropathic animals. Rats given paclitaxel plus 10 mg/kg 
melatonin in drinking water had less mechanical hypersensitivity than rats given paclitaxel plus 
vehicle throughout the time course of the model. (Fig 3A-C, p<0.0001). Comparison of the 
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effect of 10 mg/kg/day melatonin given as oral gavage or drinking water, using AUC analysis 
of data from day 2-17 after paclitaxel administration started, revealed that the melatonin effect 
was not dependent on the administration route (Fig 3C, melatonin p<0.0001; interaction 
p=0.49).  Serum melatonin levels on day 42 in animals given melatonin were significantly 
higher than those which received vehicle (Fig 3D, p=0.001). Given that administration of 
melatonin in drinking water was as effective, but less problematic than the oral gavage route, 
melatonin was administered in drinking water for the remainder of the behavioural studies. 
When melatonin was given as an intervention to rats with established paclitaxel-induced 
mechanical hypersensitivity, there was no difference between AUC withdrawal threshold (day 
20-30) values of groups receiving melatonin or vehicle control (Fig 4). Additionally, both were 
significantly lower than AUC values of the group receiving paclitaxel and melatonin throughout 
(p<0.01), suggesting melatonin was not an effective intervention to the established phenotype. 
However, when melatonin treatment was started before paclitaxel and then stopped once the 
hypersensitivity phenotype was apparent, AUC (day 20-30) analysis indicated that withdrawal 
thresholds remained higher than rats receiving paclitaxel without melatonin (p<0.0001) and 
were indistinguishable from those given melatonin continuously (Fig 4), suggesting that 
melatonin administration had a preventative effect, that persisted beyond the cessation of 
treatment. 
 
3.2.3 Peripheral nerve 8-isoprostane F2α levels 
8-isoprostane F2 levels were measured ex vivo in sciatic and saphenous nerve tissue 
collected at the peak of the model and normalised to sample protein content. Increased 8-
isoprostane F2 levels were found in peripheral nerve tissue from paclitaxel treated rats (Fig 
5A, p=0.003). Melatonin treatment was found to significantly reduce the elevated 8-
isoprostane F2 levels in paclitaxel treated rats (Fig 5B, p=0.0015). 
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3.2.4 C fibre activity-dependent slowing   
Treatment with paclitaxel with and without melatonin had no effect on C fibre threshold 
stimulus intensity, amplitude, average conduction velocity or initial response width, indicative 
of the initial range of conduction velocities within the C fibre population (Table 1). 
Repetitive stimulation of isolated dorsal roots produced a progressive increase in C fibre 
response width (Fig 6A and B). AUC analysis confirmed that this C fibre ADS was frequency-
dependent, with stimulation at 2Hz producing greater ADS than at 1Hz (p<0.0001, Fig 6C). C 
fibre ADS was lower in rats treated with paclitaxel (p<0.001), an effect that was prevented by 
melatonin (p<0.0001), independent of stimulation frequency.  
 
3.2.5 Combination treatment with duloxetine 
Paclitaxel produced mechanical hypersensitivity in male and female animals that was 
significantly ameliorated by melatonin administered in drinking water in both sexes (Fig 7). 
Duloxetine limited mechanical hypersensitivity to an extent comparable with melatonin in both 
sexes (Fig 7). Co-treatment of paclitaxel-treated animals with melatonin in drinking water plus 
duloxetine injections, revealed a clear additive effect, with higher withdrawal thresholds in co-
treated animals compared to those given either melatonin (males p<0.05) or duloxetine alone 
(males p<0.0001; females p<0.05).  
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4. Discussion 
We have shown that in vitro, paclitaxel treatment caused mitochondrial dysfunction in DRG 
cells, with reduced membrane potential and metabolic activity, and evidence of mitochondrial 
swelling. However when the cells were treated with paclitaxel plus melatonin, mitochondrial 
damage was attenuated. Importantly, co-treatment of breast or ovarian cancer cells with 
melatonin had no impact on the cytotoxicity of paclitaxel. In a rat model of paclitaxel-induced 
neuropathic pain we found that oral melatonin pre-treatment was protective, whether given as 
a bolus or in drinking water. Furthermore, melatonin reduced paclitaxel elevated peripheral 
nerve 8-isoprostane F2α levels and prevented paclitaxel reduced C fibre ADS.  When given in 
a prophylactic manner, melatonin significantly attenuated paclitaxel-evoked mechanical 
hypersensitivity in both male and female animals, and there was an additive affect when 
melatonin was given along with duloxetine. Melatonin treatment was well tolerated with no 
effects on animals’ weight gain, general well-being and sedation levels. This work suggests 
that melatonin may be a useful preventive treatment for chemotherapy-induced painful 
neuropathy in patients. 
Melatonin is known to be an effective antioxidant, and many of its reaction products and 
metabolites (e.g. 6-hydroxymelatonin) also possess antioxidant activity.15,16 Melatonin is able 
to cross cell membranes and is reported to concentrate particularly inside mitochondria.35 
where it may potentially interact with mitochondrial MT1 receptors to modulate mitochondrial 
function.36,37 Mitochondrial damage caused by paclitaxel has been reported previously in 
several cell types5,38-40 including peripheral nerve cells.6 Our in vitro data show that paclitaxel 
caused a loss of mitochondrial membrane potential and metabolic activity in DRG cells, as 
previously reported,13 and that melatonin ameliorated this damage. MitoTracker™ Green is a 
marker which fluoresces inside mitochondria, regardless of membrane potential and is an 
indicator of mitochondrial volume, reacting with free thiol groups in cysteine residues of 
mitochondrial proteins.19 The increase in observed mitochondrial volume could reflect 
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increased number of mitochondria, or mitochondrial swelling, the latter of which has been 
documented in peripheral nerve axons from paclitaxel-treated rats.6 Again melatonin 
prevented this. Moreover, these in vitro effects were in keeping with findings in vivo, where 
levels of 8-isoprostane F2α, an end product of reactions promoted in conditions of oxidative 
stress,30 were increased in peripheral nerve tissue isolated from paclitaxel treated animals, an 
effect diminished in paclitaxel treated animals co-treated with melatonin.  
Altered peripheral nerve function in the rat model of paclitaxel-induced neuropathy has been 
demonstrated with in vivo electrophysiological recordings revealing that ~30% of C fibres 
display spontaneous activity that is reduced by prophylactic treatment with acetyl-L-carnitine41, 
which is known to limit mitochondrial dysfunction.42 Altered C fibre function can also be 
characterised, in both preclinical pain models43,44 and in chronic pain patients,45-48 by 
measuring the phenomenon of C fibre ADS, which is a progressive slowing of nociceptive C 
fibre conduction velocity in response to repetitive stimulation.33,34 However, to date, this had 
not been addressed for CINP. Here we demonstrate that in peripheral nerve tissue from 
paclitaxel treated rats, C fibres had significantly lower ADS, an effect that was prevented in 
those rats co-treated with melatonin. We have very recently reported that C fibre ADS alters 
the temporal relay of pain input to the spinal cord and that a reduction in ADS, as we have 
observed in the paclitaxel model, facilitates central pain processing, and likely contributes to 
pain hypersensitivity.49 
 
The rat model of paclitaxel-induced neuropathy employed has been well characterised6,13,24 
and features mechanical hypersensitivity as indicated by the reduced mechanical threshold of 
the flexion withdrawal reflex in the present study. Melatonin given by oral gavage was both 
time consuming and stressful for the animal exemplified by the loss of 3 animals after multiple 
oral gavages. Attempts to give melatonin to individual rats in jelly cubes were unsuccessful 
and so we administered the melatonin in drinking water as described previously.50,51  There 
was no effect of melatonin on water consumption, weight gain and no apparent sedative effect 
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given there was no change in righting reflex activity, food or water intake, nor indeed altered 
mechanical sensitivity in naive animals. Furthermore, when melatonin was discontinued, the 
reduction in mechanical hypersensitivity persisted and when given as an intervention in 
animals when CINP was established, melatonin did not limit mechanical hypersensitivity, 
effects inconsistent with a melatonin ‘sedative’ effect accounting for the attenuation of CINP. 
Significantly higher serum melatonin levels at the end of the study were seen in animals given 
melatonin compared to those which did not and the magnitude of the melatonin protective 
effect was similar for rats given melatonin by bolus doses or in drinking water. We therefore 
conclude that oral melatonin pre-treatment, either as a bolus dose or in drinking water was 
effective at reducing paclitaxel-induced mechanical hypersensitivity. During these 
experiments, a melatonin dose of 10mg/kg per day was used. This dose has been 
demonstrated to be effective in reducing oxidative stress and symptom severity in pre-clinical 
models of a number of diseases, including epilepsy, diabetes, ethanol-induced neurotoxicity 
and oxidative lung toxicity.52-55 
 
The capacity of melatonin to protect against the development of paclitaxel-induced mechanical 
hypersensitivity is most likely due to its antioxidant activity. Oxidative stress occurs in 
peripheral nerves in the paclitaxel rat model56 and other antioxidant strategies, including spin 
trap agents9, mitochondrial electron transport chain modulators10 and the antioxidant 
MitoVitE13 reduce symptoms in this model. In support, we demonstrate that melatonin limits 
paclitaxel-induced elevation of 8-isoprostane F2α levels in peripheral nerves in vivo. Therefore 
although melatonin may influence pain processing via its MT1/MT2 membrane receptors and 
effects on neurotransmitter systems57 the protective effect we observe may be more likely to 
be due to its antioxidant action, perhaps via mitochondrial MT1 receptors36,37 since firstly 
melatonin prevented but did not reverse established mechanical hypersensitivity; secondly, 
the reduction in mechanical hypersensitivity produced by daily bolus administration was stable 
over 24 hours yet serum melatonin levels peak at 1h and return to baseline by 24 hours. 
Interestingly, this antioxidant protective effect fits well with the  demonstration that reactive 
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oxygen species levels peak in the DRG during the onset rather than the peak of the paclitaxel 
model,56 although it has been demonstrated that antioxidant strategies can reduce established 
paclitaxel-induced hypersensitivity.9,10 Furthermore, the recent demonstration that melatonin 
limits oxaliplatin-induced mitochondrial dysfunction and peripheral neuropathy58 suggests that 
melatonin is a potential disease modifying treatment for CINP. However, it could also be that 
melatonin antioxidant capacity combines with its receptor mediated effects upon pain 
processing to collectively provide the reduction in hypersensitivity observed. Of interest, given 
the observed additive effect of melatonin and duloxetine, agomelatine, a new class of anti-
depressant and a melatonergic and serotonergic receptor agonist, with evidence of antioxidant 
activity59,60 has very recently been shown to be effective against chemotherapy-induced 
neuropathy.61   
We also found that melatonin did not inhibit the cytotoxic action of paclitaxel in two relevant 
cancer cell lines, in agreement with studies using other antioxidants,13,62 Treatment of cancer 
patients with melatonin in several small studies did not impact on the effectiveness of 
chemotherapy63-65 and a meta-analysis of 10 randomized controlled trials of over 600 patients 
with advanced solid tumours reported that melatonin treatment reduced the risk of death at 1 
year.66 Another recent meta-analysis of 8 trials and 700 patients similarly reported that 
adjuvant melatonin treatment in patients with cancer resulted in improved 1 year survival.67 A 
more recent small trial showed no difference in survival of patients with non-small cell lung 
cancer who received 10 or 20mg melatonin daily for 6 months, although after 22 months, only 
patients given melatonin had survived, with more patients surviving who received 20mg than 
had received 10mg.68 Other studies report mechanisms of how melatonin may potentiate 
chemotherapy, reduce metastatic progression and prevent resistance to chemotherapy.69-72 
Moreover the ability of gliomas to synthesise melatonin negatively correlates with tumour 
malignancy.73 Melatonin appears to be without side effects, other than mild drowsiness.17,74 
and has been administered to thousands of patients without toxic effects, even at high doses, 
for a variety of conditions.  
19 
 
Our study clearly shows the potential of melatonin as a preventative therapeutic intervention 
for patients undergoing chemotherapy, to limit development of neuropathic pain, with no 
obvious risk to the efficacy of chemotherapy or outcome.  
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Figure Legends 
Supplemental Figure 1 
Weight gain in A, male and B, female rats treated with paclitaxel ± 10 mg/kg melatonin in 
drinking water. Weight gain was calculated from baseline measurements made 3 days prior 
to paclitaxel administration when melatonin treatment commenced. Two-Way RM ANOVA 
indicates that melatonin does not significantly alter weight gain in either sex (males, p=0.86; 
females, p=0.55). These data were obtained from the experimental groups in Figure 7. Data 
shown as mean and standard deviation (n=6 per group).  
 
Figure 1 
Effect of a range of concentrations of paclitaxel plus vehicle control (left) or plus 1µM melatonin 
(right) on A, mitochondrial membrane potential B, mitochondrial metabolic activity and C, 
mitochondrial volume, in a dorsal root ganglion neuronal cell line. Results are presented as 
percentage of data at baseline i.e. vehicle control treated cells without paclitaxel but with 
melatonin treatment. Data are shown as box and whisker plots showing median, interquartile 
and full range (n=6). P value in red is Kruskal Wallis. Asterisks = significantly different to 
without paclitaxel (*p<0.05, **p<0.01). 
 
Figure 2  
Mechanical hind paw withdrawal thresholds A, of male rats receiving paclitaxel with vehicle 
control, paclitaxel with 5 mg/kg melatonin, paclitaxel with 10 mg/kg melatonin, and paclitaxel 
with 50 mg/kg melatonin measured 6 hours after oral gavage melatonin/vehicle administration.  
AUC analysis of withdrawal thresholds B, 2-17 days following paclitaxel treatment, measured 
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at 1, 6 and 24 hours after oral gavage. Behavioural data are shown as mean (SD), n=5-6 per 
treatment group. Two-Way RM ANOVA (melatonin treatment p<0.0001) followed by Dunnett’s 
multiple comparisons test used to compare all groups to paclitaxel with vehicle control. 
*p<0.05; ***=p<0.001; ****p<0.0001. There was no significant effect of time of measure.  C, 
Serum melatonin levels from paclitaxel treated male rats given 10mg oral melatonin by 
gavage. Individual raw data points are shown (n=3).  
 
Figure 3  
Mechanical hind paw withdrawal thresholds A, of male rats receiving paclitaxel with vehicle 
control, paclitaxel with 10 mg/kg melatonin, Cremophor (paclitaxel vehicle) with vehicle control 
and saline with 10mg/kg melatonin with melatonin/vehicle administered in drinking water. AUC 
analysis of withdrawal thresholds B, 2-42 days following paclitaxel treatment. AUC analysis of 
withdrawal thresholds C, 2-17 days following paclitaxel treatment with 10mg/kg  
melatonin/vehicle administered in drinking water or by oral gavage. Behavioural data are 
shown as mean (SD), n=5-6 per treatment group. In B, One-Way ANOVA followed by Tukey 
multiple comparisons test ****p<0.0001. In C, 2-way ANOVA, melatonin treatment p<0.0001, 
interaction p=0.49. D, Serum melatonin in male rats given paclitaxel plus melatonin or vehicle 
in drinking water. Data are presented as box and whisker plots showing median, interquartile 
and full range (n=15). *** = significantly higher than rats not given melatonin (p=0.001). 
 
Figure 4  
Mechanical hind paw withdrawal thresholds A, of male rats receiving paclitaxel with vehicle 
control, paclitaxel with melatonin throughout, paclitaxel with melatonin discontinued at day 18, 
and paclitaxel with melatonin starting day 20. 10 mg/kg melatonin/vehicle administered in 
drinking water. AUC analysis of withdrawal thresholds Bi, 8-18 days or Bii, 20-30 days 
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following paclitaxel treatment. Data are shown as mean (SD), n=6 per treatment group. In B, 
One-Way ANOVA followed by Tukey’s multiple comparisons test *p<0.05; **p<0.01; 
***p<0.001;****p<0.0001.  
 
Figure 5  
8-isoprostane F2 levels in sciatic and saphenous nerve tissue isolated at day 19 of model 
from A, Cremophor (n=6) or paclitaxel (n=6) treated male rats or B, paclitaxel treated male 
rats administered 10 mg/kg melatonin by oral gavage (n=6) or vehicle/no treatment (n=11) . 
Data expressed as % change from average control cremophor values (n=12). Data are shown 
as box and whisker plots showing median, interquartile and full range. Two-Way ANOVA with 
p values indicating treatment significance.  
Figure 6 
C fibre activity-dependent slowing (ADS) recorded using Ai, two suction electrodes to 
stimulate and record compound action potentials from L4/L5 dorsal roots from male rats. Aii, 
Representative compound action potentials illustrating the slow (C) conducting component. 
The x40 traces recorded in response to 2Hz dorsal root stimulation are shown (trace 1 black; 
traces 2-39 light grey; trace 40 dark grey). Initial width (orange dashed lines) and last width 
(blue dashed lines) denoted. Repetitive stimulation of dorsal roots at 1Hz (Bi) and 2Hz (Bii) 
results in a progressive increase in response width. AUC analysis of width change C, reveals 
that the frequency dependent progressive width change (2-way ANOVA p<0.0001) is reduced 
by paclitaxel (2-way ANOVA, Tukey’s multiple comparisons test p<0.001, an effect prevented 
with 10 mg/kg/day melatonin treatment in drinking water (2-way ANOVA, Tukey’s multiple 
comparisons test p<0.0001). Data are shown as mean (SD). 
 
Figure 7  
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Mechanical hind paw withdrawal thresholds of Ai, male or Bi, female rats receiving paclitaxel, 
paclitaxel with melatonin, paclitaxel with duloxetine intervention treatment or paclitaxel with 
melatonin and duloxetine intervention treatment. 10 mg/kg/day melatonin/control administered 
in drinking water; 10mg/kg/day duloxetine/vehicle injected i.p.. AUC analysis of withdrawal 
thresholds in Aii, males or Bii, females during duloxetine intervention. Data are shown as 
mean (SD), n=6 per treatment group. In A/Bii, One-Way ANOVA followed by Tukey’s multiple 
comparisons test *p<0.05; **p<0.01; ***p<0.001;****p<0.0001.  
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Table 1: Comparison of the C fibre electrophysiological properties in dorsal roots obtained 
from the different treatment groups.  
 
 Threshold 
(µA) 
Amplitude 
(mV/mm) 
Average CV 
(m/s) 
Initial 
Response 
Width 
(ms/mm) 
Vehicle 
(n=12) 
121±9.65 0.12±0.02 0.23±0.02 4.97±0.2 
Paclitaxel 
(n=10) 
100±0 0.12±0.03 0.22±0.2 5.57±0.2 
Paclitaxel 
and 
Melatonin 
(n=12) 
104±4.17 0.13±0.02 0.21±0.01 5.10±0.3 
 
Table 1 footnote 
One–way ANOVA reveals that treatment group does not affect threshold stimulus intensity 
(p=0.08), amplitude (p=0.93), average conduction velocity (p=0.75) or the initial C fibre 
response width (p=0.23).  
 
 
